Gary Rojewski has 29-years experience in the pharmaceutical industry. During that time he has worked for Procter & Gamble Pharmaceuticals, Warner Chilcott Pharmaceuticals and most recently Actavis. Throughout his pharmaceutical career he has been responsible for commercializing pharmaceutical products.
CEO – Gary Rojewski
LATEST ENZYME BIOSYSTEMS PRESS RELEASE & NEWS
On June 9, 2014, EnzymeBiosSystems (“the Company” or the Registrant”) closed its Regulation S Offering, whereby, the Company sold 12,783,587 shares of unregistered restricted common stock to six foreign purchasers, at a price of $0.0766 per share. The total amount the Company received from this Offering was $980,000.
Change in Directors or Principal Officers Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On June 2, 2014, the Board of Directors of EnzymeBioSystems (the “Company” or the “Registrant”) unanimously appointed Mr. Gary Rojewski as Chief Executive Officers of the Company. Mr. Rojewski accepted the position. He will […]
Form 10-Q for ENZYMEBIOSYSTEMS 14-May-2014 Quarterly Report MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Item 2. – Management’s Discussion and Analysis of Financial Condition and Results of Operations Forward-Looking Information This Quarterly Report on Form 10-Q contains forward-looking statements. When used in this Quarterly Report on Form 10-Q, the words […]